Therapeutic Solutions International, Inc. Announces the Appointment of Vijay Mahant, Ph.D., M.S. to the TSI Scientific Advisory Board
October 26, 2015 08:30 ET
Oceanside, CA — October 26, 2015 — InvestorsHub NewsWire — Therapeutics Solutions International, Inc., (OTC Markets:TSOI) announced today that Vijay Mahant, Ph.D., M.S. has been appointed to our Scientific Advisory Board.
Dr. Mahant has been involved in Research and Development in the medical industry for close to 30 years. Working in the FDA regulated medical industry, he has headed R&D activities for several bio-medical companies as well as being the founder, CEO & Chairman of MediLite, Inc. Dr. Mahant has specialized in the areas of assay development, has numerous patents to his credit and has published extensively.
“We are honored indeed to welcome Dr. Mahant to our Scientific Advisory Board who joins the team of Dr. Michael G. Agadjanyan, Dr. Santosh Kesari, Dr. Harry M. Lander and Dr. Francesco M. Marincola who we previously announced. The Advisory Board will review, evaluate and report to the company Board of Directors regarding strategy, plans and goals, as well as progress and performance, of the Company’s development programs and research activities” said Timothy Dixon, President and CEO.
Dr. Mahant received his B.S. in Biochemistry from the University of Salford, UK; a M.S. in Medicinal Chemistry and a Ph.D. in Medical Biochemistry from Lougborough University of Technology, UK.
The Company’s corporate website is www.therapeuticsolutionsint.com. Our new products can be viewed on www.projuvenol.com and products can be ordered at www.youcanordernow.com.
These Supplement products have not been evaluated by the United States Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any diseases.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.